IRVING, TX--(Marketwire - February 18, 2009) - DelSite, Inc (OTCBB: DSII) today announced that
in order to protect its proprietary raw material Manapol® from cheap,
ineffective, foreign raw materials, it has initiated a licensing program
for its proprietary raw materials including Manapol®. There are
currently no agreements that preclude the broad and lawful licensing of
Manapol® is a biologic raw material produced as a "product by process"
which ensures quality and consistency. Manapol® is used in DelSite's
AloeCeuticals® product line. Manapol® is also used to fortify various
nutraceutical drinks made from fresh aloe gel.
Manapol® raw material carries the DSHEA claim of "enhances the immune
system." This claim is based on human clinical trials. Other clinical
trials of Manapol® raw material have provided DSHEA claims on digestion
and cholesterol maintenance.
A DelSite spokesperson said, "The widely held perception that one company
has the exclusive right to market Manapol® is categorically not true, as
is the notion that potential competitors of that company would be subject
to injunctions or law suits if they were to market a product containing
Manapol® after obtaining a license from DelSite. All intellectual
property related to Manapol® is owned by DelSite. There are no current
exclusive licensing agreements for Manapol® raw material or for the
trademark Manapol®. Our business model has changed. Going forward we
will license for single or multiple fields of use, for single or multiple
DSHEA claims, for manufacturing or use in individual countries or
territories, or for single product lines like drinks or multiple dosage
Clinicians in some African countries are using pure Manapol® powder to
enhance immune function in patients with impaired immune systems.
The spokesperson added that "other DelSite 'product by process' raw
materials such as Acemannan Hydrogel™ for wound healing and dental care,
HydroPol™ for cosmetic and nutraceutical use, VeraPol™ for
nutraceutical, as well as Acemannan Immunostimulant™, a USDA approved
biologic for the treatment of certain cancers in cats and dogs, will also
Interested parties can call Mr. Robert Schnitzius, DelSite's CFO and acting
CEO, at (972) 518-1300.
DelSite, Inc. is an ISO 9001-certified, research-based, biopharmaceutical
and consumer products company with a core technology based on naturally
occurring complex carbohydrates. DelSite also manufactures and markets
consumer products and manufactures quality products for other companies.
Manufacturing operations comply with cGMP standards. DelSite is developing
its proprietary GelSite® technology designed to provide controlled
release of peptide and protein-based drugs. More than 130 patents in 26
countries protect its technology.
Certain statements in this release concerning DelSite may be
forward-looking. Actual events will be dependent upon a number of factors
and risks including, but not limited to: subsequent changes in plans by
the Company's management; delays or problems in formulation, manufacturing,
distribution, production and/or launch of new finished products; changes in
the regulatory process; changes in market trends; and a number of other
factors and risks described from time to time in the Company's filings with
the Securities & Exchange Commission.